Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, discussed results from the ARCHWAY phase 3 trial of the Port Delivery System with ranibizumab presented at the ASRS annual meeting.
“This treatment was equivalent to monthly ranibizumab injections. In a year’s period of time, you have the initial surgery, a 6-month refill and then a 6-month refill after that,” she said in a video interview with Healio. “That’s really remarkable, and the data is very, very strong.”
However, treatment-emergent adverse events occurred,